Cointime

Freeline

company

About

Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.

  • 101 - 250

Highlights

Total Funding Amount
$80M
Funding Rounds
1
Investors
1
Investments
2

Details

Last Funding Type
Series C
Last Funding Money Raised
$80M
Industries
Biopharma,Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
101 - 250
Operating Status
Active

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$80M
Freeline has raised a total of $80M in funding over 2 rounds. Their latest funding was raised on Jun 30, 2020 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 30, 2020 Series C $80M 1 — — Detail

Investments

Number of Investments
Number of Lead Investments
2
0
Freeline has made 2 investments. Their most recent investment was on Aug 8, 2022, when Betr raised $20M.
Date Company Name
Round Money Raised Industry Lead Investor
Aug 8, 2022 Betr
Series A $20M Gambling —
Apr 13, 2022 MoonPay
Series A $87M Financial Services —

Investors

Number of Lead Investors
Number of Investors
—
1
Freeline is funded by 1 investors. Ample Plus Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Ample Plus Fund — Series C
Cointime
เนื้อหา
บริษัท